{"authors": [["Desormais", "Il\u00e9ana", "I", "Faculty of Medicine, Tropical Neuroepidemiology, Inserm UMR 1094, 2, rue du Docteur-Marcland, 87025 Limoges, France; CHU Dupuytren, service de chirurgie vasculaire et thoracique-m\u00e9decine vasculaire, 2, avenue M.L.-King, 87042 Limoges cedex, France."], ["Aboyans", "Victor", "V", "Faculty of Medicine, Tropical Neuroepidemiology, Inserm UMR 1094, 2, rue du Docteur-Marcland, 87025 Limoges, France; CHU Dupuytren, service de cardiologie, 2, avenue M.L.-King, 87042 Limoges cedex, France."], ["Pesteil", "Francis", "F", "CHU Dupuytren, service de chirurgie vasculaire et thoracique-m\u00e9decine vasculaire, 2, avenue M.L.-King, 87042 Limoges cedex, France."], ["Lacroix", "Philipe", "P", "Faculty of Medicine, Tropical Neuroepidemiology, Inserm UMR 1094, 2, rue du Docteur-Marcland, 87025 Limoges, France; CHU Dupuytren, service de chirurgie vasculaire et thoracique-m\u00e9decine vasculaire, 2, avenue M.L.-King, 87042 Limoges cedex, France. Electronic address: philippe.lacroix@unilim.fr."]], "date": "2017-12-19", "id": "29273182", "text": "Medical management of peripheral arterial disease (PAD) patients is aimed at limb symptom relief and reducing systemic major adverse events risk. For the first purpose: exercise therapy is recommended in case of claudication; multidisciplinary evaluation for surgical options is mandatory in case of critical limb ischaemia. Reducing cardiac and stroke risk can be achieved through: statin prescription in most of the cases; antiplatelet agents in symptomatic PAD patients; cardio-vascular risk factors control.", "doi": "10.1016/j.lpm.2017.09.019", "title": "[Peripheral arterial disease: Treatment].", "journal": ["Presse medicale (Paris, France : 1983)", "Presse Med"]}